About Ronald Seidel III
Ronald Seidel, III is Crosslink Therapeutics' chief executive officer and a director; the company develops medicines for people with solid tumors, designed to assemble inside those tumors.
Experience
This experience comes from Ronald Seidel III's profile and from SEC filings. For roles taken from filings, the years are when the filings name Ronald Seidel III in the role, so the role may have started earlier or lasted longer.
Crosslink Therapeutics Inc. Current
Co-founder and CEO, director
Chief Executive Officer and Director
2025 – Present · Boston, MA
Crosslink builds a modular biologic platform for antibody-drug conjugates and radioligand therapies.
RT
R Therapeutics Current
Founder and CSO
2021 – Present
CI
Cue Biopharma, Inc.
EVP, Head of R&D
Senior Scientific Advisor (2015 – 2022)
2015 – 2022 · Public company (CUE)
AM
Albert Einstein College of Medicine
Research Assistant Professor and Associate Director, Macromolecular Therapeutic Development
2008 – 2015
NC
New York Structural Biology Center
Post-Doctoral Research Associate
2005 – 2008
Key Colleagues at Startups
The people Ronald Seidel III works with at each company, as listed on that company's latest Form D.
Crosslink Therapeutics Inc. · Form D, Oct 20, 2026
AK
Andrew King
Director
Lou Tartaglia
Director
Rodolfo Chaparro
Co-Founder and Scientific Advisor, director
David Fallace
Director
Cameron Gallagher
Chairman